XML 87 R66.htm IDEA: XBRL DOCUMENT v2.4.0.8
Components of Deferred Tax Assets, Deferred Tax Liabilities, and Liability for Unrecognized Tax Benefits Included in Allocation of Crescendo's Purchase Consideration (Detail) (USD $)
Jun. 30, 2014
Jun. 30, 2013
Feb. 28, 2014
Crescendo Biosciences, Inc.
Deferred tax assets:      
Net operating loss carryforwards $ 76,986,000 $ 8,336,000 $ 70,048,000
Research and development credits 11,207,000 5,367,000 5,815,000
Other, net 312,000 643,000 312,000
Total gross deferred tax assets 122,795,000 45,295,000 76,175,000
Less valuation allowance (41,420,000) (8,218,000) (29,760,000)
Total deferred tax assets 81,375,000 37,077,000 46,415,000
Deferred tax liabilities:      
Intangible assets 71,750,000 438,000 72,005,000
Stock compensation expense     4,443,000
Total deferred tax liabilities 71,750,000 438,000 76,448,000
Net deferred tax liability     30,033,000
Liability for unrecognized tax benefits $ 24,238,000 $ 10,718,000 $ 14,180,000